BioSpace News Archive

Neurona Therapeutics, a biotherapeutics company advancing restorative neural cell therapies for the treatment of chronic neurological disorders, today announced that it has appointed Brad Margus to its board of directors.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 3, 2021 at 4:00 PM Eastern Time.

SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release third quarter financial results after the close of trading on Thursday, October 28, 2021.

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, Oct. 27, 2021 to discuss the company’s third quarter 2021 financial results.

Benchmark Electronics, Inc. (NYSE: BHE) will announce its third quarter 2021 results on Wednesday, October 27, 2021, after the market closes.

NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced operational progress and cash position (unaudited) for the third quarter of 2021.

A Senior Principal Data Scientist from a leading global pharmaceutical company showcased its success stories of using Pangaea Data’s novel artificial intelligence driven product, PIES (Pangaea’s Intelligence Extractor and Summarization).

Inventiva (Euronext Paris and Nasdaq: IVA), today announced the publication of the results from its NATIVE (NAsh Trial to Validate IVA337 Efficacy) Phase IIb clinical trial evaluating lanifibranor for the treatment of NASH in the prestigious, peer-reviewed medical journal The New England Journal of Medicine (NEJM).

Today, the U.S. Food and Drug Administration took action to expand the use of a booster dose for COVID-19 vaccines in eligible populations.

MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the first patient has been dosed in the Phase 2 IGNAZ clinical trial evaluating felzartamab for patients with Immunoglobulin A Nephropathy (IgAN).